Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis

INTRODUCTION: Sipuleucel-T is a novel active cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). It is assumed to be associated with less adverse events than conventional docetaxel-based chemotherapy. MATERIAL AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawalec, Paweł, Paszulewicz, Anna, Holko, Przemysław, Pilc, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2012
Materias:
Systematic review/Meta-analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506233/
https://www.ncbi.nlm.nih.gov/pubmed/23185184
http://dx.doi.org/10.5114/aoms.2012.31610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506233/
https://www.ncbi.nlm.nih.gov/pubmed/23185184
http://dx.doi.org/10.5114/aoms.2012.31610

Ejemplares similares